MedNews

  • Drug Industry News
  • FDA News & Alerts
  • Health & Medical News
You are here: Home / Health & Medical News / Alzheimer's / Novartis Receives FDA Approval for Exelon Skin Patch to Treat Alzheimer’s Disease

Novartis Receives FDA Approval for Exelon Skin Patch to Treat Alzheimer’s Disease

July 9, 2007 By MedNews Leave a Comment

Swiss drug maker Novartis AG Monday said it received approval from the U.S. Food and Drug Administration for its Exelon skin patch for the treatment of Alzheimer’s disease.

Novartis, based in Basel, said this was the first approval world-wide for the patch, which delivers the medicine for mild to moderate Alzheimer’s disease patients through a skin patch instead of an oral capsule.

Filed Under: Alzheimer's Tagged With: alzheimers, Exelon, novartis



Leave a Reply

Your email address will not be published. Required fields are marked *

Search



Tag Cloud

alcohol allergies alzheimers antibiotics breast cancer cancer Centers for Disease Control (CDC) children cholesterol dementia depression Diabetes diet drug abuse exercise fda flu food genetics geriatrics h1n1 heart heart attack heart disease high blood pressure HIV/AIDS hormone therapy hypertension lungs menopause NIH obesity pain pediatrics pregnancy prostate cancer seniors sleep smoking statistics stroke sun teens USA women's health

Recent Comments

  • Mia Fritz on Health Benefits of Dark Chocolate
  • Shilpa on Why Too Much Iron Can Be Dangerous
  • Racheal on Teen Pregnancy May Be Reduced by Sex Education in Schools, Says Study
  • Don on Prilosec, Nexium and Prevacid Tied to Higher Risk of Pneumonia
  • Meso on Brain Changes in Elderly Can Affect Mobility and Balance
  • About Us
  • Contact

Copyright © 2025 Mednews · Log in